JP2019505597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505597A5 JP2019505597A5 JP2018563393A JP2018563393A JP2019505597A5 JP 2019505597 A5 JP2019505597 A5 JP 2019505597A5 JP 2018563393 A JP2018563393 A JP 2018563393A JP 2018563393 A JP2018563393 A JP 2018563393A JP 2019505597 A5 JP2019505597 A5 JP 2019505597A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- ring
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 claims 5
- 101150094373 Padi4 gene Proteins 0.000 claims 5
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Chemical group 0.000 claims 4
- 229910052717 sulfur Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 208000004852 Lung Injury Diseases 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 231100000515 lung injury Toxicity 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000027932 Collagen disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 206010035742 Pneumonitis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000003814 drug Chemical group 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000007794 irritation Effects 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 claims 1
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 claims 1
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000020576 Adrenal disease Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010003402 Arthropod sting Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000006373 Bell palsy Diseases 0.000 claims 1
- 208000009766 Blau syndrome Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 241000282461 Canis lupus Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000007336 Cryptococcosis Diseases 0.000 claims 1
- 241000221204 Cryptococcus neoformans Species 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 241001475178 Dira Species 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 201000011275 Epicondylitis Diseases 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000035690 Familial cold urticaria Diseases 0.000 claims 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims 1
- 206010070531 Foetal growth restriction Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims 1
- 206010020565 Hyperaemia Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010024238 Leptospirosis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010070594 PFAPA syndrome Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 241001442654 Percnon planissimum Species 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039792 Seborrhoea Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000004760 Tenosynovitis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 241000159243 Toxicodendron radicans Species 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 229910052790 beryllium Inorganic materials 0.000 claims 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000002561 chemical irritant Substances 0.000 claims 1
- 201000004018 childhood brain stem glioma Diseases 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002169 ectodermal dysplasia Diseases 0.000 claims 1
- 208000030941 fetal growth restriction Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 201000003535 hypohidrotic ectodermal dysplasia Diseases 0.000 claims 1
- 208000035128 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 10B Diseases 0.000 claims 1
- 208000032771 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 11B Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000006747 infectious mononucleosis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 1
- 230000035987 intoxication Effects 0.000 claims 1
- 231100000566 intoxication Toxicity 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 201000000317 pneumocystosis Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000010346 psychosocial stress Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 0 C*ICC(C)(CC1)CC(CC(C)(C)*)CCC1C(*(*)C1=C)=*C1=CC(C(CC1CCCCCCCCC1)=O)=C* Chemical compound C*ICC(C)(CC1)CC(CC(C)(C)*)CCC1C(*(*)C1=C)=*C1=CC(C(CC1CCCCCCCCC1)=O)=C* 0.000 description 5
- YSHLVNOVNXNSQS-UHFFFAOYSA-N CN(CC(C1)N)CC1F Chemical compound CN(CC(C1)N)CC1F YSHLVNOVNXNSQS-UHFFFAOYSA-N 0.000 description 1
- QZSACHHNFDNCNB-UHFFFAOYSA-N CN(CCC1)CC1N Chemical compound CN(CCC1)CC1N QZSACHHNFDNCNB-UHFFFAOYSA-N 0.000 description 1
- DYXHMBATAKKMTQ-OAQYLSRUSA-N N[C@H](CCC1)CN1C(c(cc1)cc2c1[n](C=[IH])c(-c1cc(-c3ccccc3)n[n]1CC1CC1)n2)=O Chemical compound N[C@H](CCC1)CN1C(c(cc1)cc2c1[n](C=[IH])c(-c1cc(-c3ccccc3)n[n]1CC1CC1)n2)=O DYXHMBATAKKMTQ-OAQYLSRUSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298726P | 2016-02-23 | 2016-02-23 | |
| US62/298,726 | 2016-02-23 | ||
| PCT/US2017/018790 WO2017147102A1 (en) | 2016-02-23 | 2017-02-22 | Heteroaryl inhibitors of pad4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505597A JP2019505597A (ja) | 2019-02-28 |
| JP2019505597A5 true JP2019505597A5 (enExample) | 2020-04-02 |
| JP6926126B2 JP6926126B2 (ja) | 2021-08-25 |
Family
ID=58191708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563393A Active JP6926126B2 (ja) | 2016-02-23 | 2017-02-22 | Ｐａｄ４のヘテロアリール阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11198681B2 (enExample) |
| EP (1) | EP3419969B1 (enExample) |
| JP (1) | JP6926126B2 (enExample) |
| KR (1) | KR102759005B1 (enExample) |
| CN (1) | CN109071497B (enExample) |
| AR (1) | AR107694A1 (enExample) |
| AU (1) | AU2017223416A1 (enExample) |
| BR (1) | BR112018016433A2 (enExample) |
| CA (1) | CA3015482A1 (enExample) |
| EA (1) | EA201891910A1 (enExample) |
| ES (1) | ES2770102T3 (enExample) |
| IL (1) | IL261167A (enExample) |
| MX (1) | MX2018009773A (enExample) |
| SG (1) | SG11201807021UA (enExample) |
| TW (1) | TW201825476A (enExample) |
| UY (1) | UY37134A (enExample) |
| WO (1) | WO2017147102A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201807021UA (en) | 2016-02-23 | 2018-09-27 | Padlock Therapeutics Inc | Heteroaryl inhibitors of pad4 |
| US10703741B2 (en) | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
| KR102502992B1 (ko) | 2016-09-12 | 2023-02-24 | 패들락 테라퓨틱스, 인코포레이티드 | Pad4의 헤테로아릴 억제제 |
| JP7504349B2 (ja) * | 2017-09-19 | 2024-06-24 | 三菱瓦斯化学株式会社 | 半導体リソグラフィー膜形成組成物、並びにレジストパターン形成方法及びデバイス |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| WO2019122202A1 (en) * | 2017-12-20 | 2019-06-27 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| ES2929200T3 (es) * | 2018-08-08 | 2022-11-25 | Bristol Myers Squibb Co | Tienopirroles sustituidos como inhibidores de PAD4 |
| ES2956090T3 (es) | 2018-08-08 | 2023-12-13 | Bristol Myers Squibb Co | Inhibidores de bencimidazol de enzimas PAD |
| EP3833440A1 (en) | 2018-08-08 | 2021-06-16 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
| JP7345220B2 (ja) * | 2019-08-30 | 2023-09-15 | ティーエスディー ライフ サイエンス カンパニー リミテッド | イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物 |
| TW202115083A (zh) * | 2019-09-27 | 2021-04-16 | 大陸商南京藥捷安康生物科技有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| CN115298175B (zh) | 2020-02-06 | 2024-05-07 | 百时美施贵宝公司 | 可用作免疫抑制剂的大环pad4抑制剂 |
| CN113248507A (zh) * | 2020-02-09 | 2021-08-13 | 上海茂晟康慧科技有限公司 | 瑞德西韦关键中间体7-卤代吡咯并[1,2-f][1,2,4]三嗪-4-胺的合成方法 |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| MX2022013615A (es) | 2020-04-30 | 2022-11-16 | Gilead Sciences Inc | Inhibidores de macrociclo de peptidilarginina deiminasas. |
| CN112618546B (zh) * | 2020-12-22 | 2022-03-01 | 陈昊 | Pad4抑制剂在制备放射治疗增敏药物方面的应用 |
| EP4267562A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| KR20220122879A (ko) * | 2021-02-26 | 2022-09-05 | 주식회사 티에스디라이프사이언스 | 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 |
| KR20260011143A (ko) | 2023-04-18 | 2026-01-22 | 칼리오페, 인크. | Nk3 조정제 및 이의 용도 |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2025080781A1 (en) * | 2023-10-12 | 2025-04-17 | Kallyope, Inc. | Nk3 modulators and uses thereof |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2611010C2 (ru) | 2012-07-26 | 2017-02-17 | Глаксо Груп Лимитед | 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4 |
| WO2016185279A1 (en) * | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| AR107032A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| SG11201807021UA (en) | 2016-02-23 | 2018-09-27 | Padlock Therapeutics Inc | Heteroaryl inhibitors of pad4 |
| US10703741B2 (en) | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
| KR102502992B1 (ko) | 2016-09-12 | 2023-02-24 | 패들락 테라퓨틱스, 인코포레이티드 | Pad4의 헤테로아릴 억제제 |
-
2017
- 2017-02-22 SG SG11201807021UA patent/SG11201807021UA/en unknown
- 2017-02-22 EP EP17708142.9A patent/EP3419969B1/en active Active
- 2017-02-22 ES ES17708142T patent/ES2770102T3/es active Active
- 2017-02-22 BR BR112018016433-0A patent/BR112018016433A2/pt not_active IP Right Cessation
- 2017-02-22 AR ARP170100442A patent/AR107694A1/es unknown
- 2017-02-22 EA EA201891910A patent/EA201891910A1/ru unknown
- 2017-02-22 CA CA3015482A patent/CA3015482A1/en not_active Abandoned
- 2017-02-22 TW TW106105844A patent/TW201825476A/zh unknown
- 2017-02-22 AU AU2017223416A patent/AU2017223416A1/en not_active Abandoned
- 2017-02-22 KR KR1020187027136A patent/KR102759005B1/ko active Active
- 2017-02-22 JP JP2018563393A patent/JP6926126B2/ja active Active
- 2017-02-22 WO PCT/US2017/018790 patent/WO2017147102A1/en not_active Ceased
- 2017-02-22 MX MX2018009773A patent/MX2018009773A/es unknown
- 2017-02-22 UY UY0001037134A patent/UY37134A/es unknown
- 2017-02-22 CN CN201780025089.9A patent/CN109071497B/zh active Active
- 2017-02-22 US US16/078,376 patent/US11198681B2/en active Active
-
2018
- 2018-08-15 IL IL261167A patent/IL261167A/en unknown
-
2021
- 2021-11-09 US US17/522,348 patent/US11897866B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505568A5 (enExample) | ||
| CN109790162A (zh) | Pad4的共价抑制剂 | |
| RU2673889C1 (ru) | Стабильная кристаллическая форма ii апремиласта, не содержащая сольваты, и способ ее получения | |
| JP2019525936A5 (enExample) | ||
| US12201639B2 (en) | Aqueous oral pharmaceutical suspension compositions | |
| ES2295682T3 (es) | Derivados de pirimidina y su uso como modulares de cb2. | |
| JP5346292B2 (ja) | ５−ｈｔ２ａセロトニン受容体に関連する障害の処置に有用な５−ｈｔ２ａセロトニン受容体の調整因子としてのピラゾール誘導体 | |
| BR112020002906A2 (pt) | novos compostos de sulfonamida-carboxamida | |
| BR112017007953B1 (pt) | Forma cristalina ii do bissulfato inibidor de jak quinase, seu uso e seu método de preparação, e composição farmacêutica | |
| ES2971478T3 (es) | Formas en estado sólido de sofosbuvir | |
| US20100190812A1 (en) | Nilotinib hcl crystalline forms | |
| CN109071497A (zh) | Pad4杂芳基抑制剂 | |
| BR112012023649B1 (pt) | Método para produção de cristais de forma ii de monoidrato de n1 -(5-cloropiridin-2-il)-n2 -((1s,2r,4s)-4-[(dimetilamino) carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino}ciclohexil)etanodiamida p-toluenossulfonato | |
| JP2001523712A (ja) | Ｐｄｅ−ｉｖのベンゼンスルホンアミド阻害剤およびそれらの治療的使用 | |
| JP2011506554A (ja) | Ｐ２ｘ７調節因子としての５−オキソ−３−ピロリジンカルボキサミド誘導体 | |
| JP7818900B2 (ja) | ６－［（３Ｓ，４Ｓ）－４－メチル－ｌ－（ピリミジン－２－イルメチル）ピロリジン－３－イル］－３－テトラヒドロピラン－４－イル－７Ｈ－イミダゾ［ｌ，５－Ａ］ピラジン－８－オンの一水和物および結晶形態 | |
| US11767319B2 (en) | Crystalline forms of a selective c-kit kinase inhibitor | |
| SU1588284A3 (ru) | Способ получени производных 1Н, 3Н-пирроло [1,2-с] тиазола в форме рацематов или энантиомеров | |
| EA031671B1 (ru) | Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения | |
| CN112313233A (zh) | Jak家族激酶的小分子抑制剂 | |
| JP2004520423A5 (enExample) | ||
| WO2024179422A1 (zh) | Aficamten的共晶及其制备方法和用途 | |
| JP2004505979A (ja) | ザレプロンの多形及びそれらの調製方法 | |
| CZ305213B6 (cs) | Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy | |
| WO2024237816A1 (ru) | Новые производные азабициклогексана |